



Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Registered Office:

3rd Floor, Srivalli's Corporate, Plot No.290, Road No.6,
Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills,
Hyderabad, Shaikpet, Telangana, India-500033

T: +91 40 23635000,

E: investorrelations@viyash.com

Website: www.viyash.com

CIN: L99999TS1985PLC196357

June 8, 2026

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza,
Bandra-Kurla Complex,
Bandra (East),
Mumbai - 400 051

Scrip code: 512529

Scrip code: VIYASH

Dear Sir/ Madam,

Subject: Press Release – Viyash Scientific Further Strengthens Its European Companion Animal Presence with Acquisition of Italy's BioForLife

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on the captioned subject which is self-explanatory.

This is for your information and appropriate dissemination.

Thanking you,

Yours faithfully,

For Viyash Scientific Limited

(Formerly known as Sequent Scientific Limited)

Yoshita Vora

Company Secretary & Compliance Officer

Encl: A/a



Viyash Scientific Further Strengthens European Companion Animal Presence with Acquisition of Italy's BioForLife

Acquisition marks strategic entry into one of Europe's largest companion animal health markets and accelerates global pet care growth ambition

Hyderabad June 8, 2026: Viyash Scientific Limited (Viyash), through its wholly owned subsidiary Alivira Animal Health Limited (Alivira), has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. (BFL), a leading pet care company based in Milan, Italy. The acquisition, for a cash consideration of ~₹ 188 crore is expected to close in Q2 FY27. The transaction represents a significant step in Viyash's strategy to capitalize on the mega-trend of a growing Companion Animal Health Generics market. It expands Alivira's global Companion Animal Health business and strengthens its presence in the European pet care market.

Italy is among the five largest animal health markets in Europe, with companion animal care emerging as its fastest-growing segment driven by rising pet ownership, increasing pet humanization trends and higher spending on preventive and specialized veterinary care.

BioforLife, based in Milan, Italy, specializes in the development, commercialization and distribution of pet care products. With a strong product portfolio and pipeline for pet health, BFL has established strong positions in nutritional complements, pharmaceuticals, and rapid diagnostic tests. BFL is also building a business in fast growing segments like dermatology and ophthalmology. With a well-established front-end sales team, BFL reaches over 80% of all veterinary clinics in Italy, thereby providing well-established customer relationships for future growth.

The acquisition will provide a platform for launching new products from Alivira's pipeline in Italy, while simultaneously providing opportunities to expand the BFL range to other markets in the Alivira group located in Europe, Middle East, Asia and Latam.

Commenting on the acquisition, **Dr. Haribabu Bodeputi, Managing Director and Group CEO, Viyash Scientific Limited**, said: *"This acquisition represents another important step in our strategy to build a leading global Companion Animal Health business. BioForLife provides us with an established platform in Italy, one of Europe's most attractive pet care markets, while strengthening our presence across the region. The combination of BioForLife's commercial reach and Alivira's product development capabilities creates a compelling opportunity to accelerate growth, expand our companion animal portfolio and deliver greater value to veterinarians, pet owners and partners across markets. We also see meaningful opportunities*



to introduce innovative products into India and other geographies through our global reach. This investment reflects our continued commitment to sustainable growth, strategic expansion and long-term value creation."

This transaction also strengthens the Alvira team with the induction of BFL executives who will continue to run the business operations, in addition to driving new growth initiatives.

This transaction further builds on Alvira's strong track record of global acquisitions, having successfully acquired and integrated animal health companies across Europe, Latam and Asia in the last 10 years.

About Viyash Scientific Limited

Viyash Scientific Limited (formerly known as Sequent Scientific Limited) headquartered in India is globally among the leading Animal Health companies. With over 3,000 talented employees, Viyash Scientific Limited is an integrated pharmaceutical company having a rich portfolio of formulations and APIs for human and veterinary use, serving customers in 100+ countries. Viyash and its subsidiaries have manufacturing, R&D and distribution operations across India, Spain, Brazil, Turkey and USA, with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc.

For details, feel free to contact

Yoshita Vora, Company Secretary

Tel: +91 22 4111 4717

investorrelations@viyash.com

Abhishek Singhal, Investor Relations Consultants

abhishek@arunya.co.in

Registered Office

3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana

CIN: L99999TS1985PLC196357

BSE Code: 512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Website: www.viyash.com